课题基金 / 基金详情

"Biological effects of soluble recombinant CD40 ligand and interferon-γ on human renal cancer cell lines in vitro and in vivo."

"Biological effects of soluble recombinant CD40 ligand and interferon-γ on human renal cancer cell lines in vitro and in vivo."
“可溶性重组 CD40 配体和干扰素-γ 对人肾癌细胞系的体外和体内生物学效应。”
批准号:
10671497
负责人:
FUJII Tsunehiro
金额:
$0.83万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1998
资助国家:
日本
项目状态:
已结题
起止时间:
1998 至 1999

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. Surface expression of CD40 on human renal cancer cell line.Immunofluorescence studies were performed by flow cytometric analysis. CD40 was expressed on various human renal cancer cell lines, 769-P, 786-O, A-498 and A-704.2. Induction of CD40 expression by interferon-γ in vitro.Incubation with interferon-g significantly induced surface expression on human renal cancer cell lines.3. Antitumor effects of soluble recombinant CD40 lingand (srCD40L) and interferon-γ on human renal cancer cell lines in vitro.Incubation with srCD40L significantly inhibited the proliferation of 769-P and 786-O as determined by the proliferation assay with optimal inhibition of thymidine incorporation. Apoptotic studies by flow cytometry revealed an induction of apoptosis in these two cell lines. Additional inhibitory effect by co-incubation with interfron-γ significantly enhanced this inhibitory effects.4. Antitumor effects of srCD40L treatment in SCID mice bearing human human renal cancer cell lines.Effects of srCD40L treatment on survival in human renal cancer cell-bearing SCID mice were determined. All mice received 20 μL of anti-asialo GMI (Wako Chemicals, Osaka) by intravenous injection (IV) 1 day before tumor transfer to remove host natural killer cells. 769-P cells (5 x l0ィイD16ィエD1) were then administered by IV. SCID recipients then received either l0 μg of srCD40L or controll every other day for 20 days for total of 10 injections starting at day 3. Tumor bearing mice were then monitored for tumor development and progression. Treatment with srCD40L significantly improved the survival of tumor-bearing mice (p<0.05).We are preparing a manuscript from these data for Japanese Journal for Cancer Research.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金